B7-H3 Recombinant Rabbit Monoclonal Antibody (PD00-36), Invitrogen™
Manufacturer: Thermo Scientific
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | FEMA550756-Each-of-1 | In Stock | ₹ 42,275.00 |
FEMA550756 - Each of 1
In Stock
Quantity
1
Base Price: ₹ 42,275.00
GST (18%): ₹ 7,609.50
Total Price: ₹ 49,884.50
Antigen
B7-H3
Classification
Recombinant Monoclonal
Concentration
1 mg/mL
Formulation
PBS with 0.1% BSA, 40% glycerol and 0.05% sodium azide; pH 7.4
Gene Accession No.
Q5ZPR3
Gene Symbols
CD276
Immunogen
Synthetic peptide aa 480-534/534.
Quantity
100 μL
Primary or Secondary
Primary
Target Species
Human
Form
Liquid
Applications
Flow Cytometry, Immunohistochemistry (Paraffin)
Clone
PD00-36
Conjugate
Unconjugated
Gene
CD276
Gene Alias
4Ig-B7-H3, 6030411F23Rik, AU016588, B7 homolog 3, B7h3, B7-H3, B7RP-2, CD276, CD276 antigen, CD276 molecule, CD276 molecule tv1, costimulatory molecule, PSEC0249, sB7 H3, sB7H3, sCD276, soluble B7 H3, soluble B7H3, soluble CD276, UNQ309/PRO352
Host Species
Rabbit
Purification Method
Protein A
Regulatory Status
RUO
Gene ID (Entrez)
80381
Content And Storage
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
Isotype
IgG
Related Products
Description
- Positive control: Human lung squamous cell carcinoma tissue, human lung adenocarcinoma tissue, human prostate carcinoma tissue, HEK-293, THP-1
- Predicted band size: 57 kDa Subcellular Location: Membrane
- CD276 is a member of the B7 family of co-stimulatory molecules also known as B7-H3
- CD276 is a type I transmembrane protein that induces the proliferation of CD4+ and CD8+ T cells, enhances the generation of cytotoxic T cells and selectively stimulates the production of interferon gamma
- Expression of CD276 can be induced on dendritic cells and monocytes by inflammatory cytokines, and is also widely expressed in peripheral tissues including the heart, kidney, testis and colon
- In humans, CD276 exists as two isoforms which result from gene duplication and differential splicing
- CD276 is reported to have therapeutic potential for the regulation of cell-mediated immune responses to cancer, particularly in conjunction with anti-angiogenic therapy.